DBV Technologies (DBVT) logo

DBV Technologies (DBVT) stock

Allergy skin patches , market cap $592M

$9.02
-4.25%

Quality Score
-7
Poor
In its industry
#227of 273
Checks firing
1of 14
Trending down
From 52-week high
-65.6%
under its best in a year

DBVT's Quality Score rose 1 point on Fri, Nov 20, to -7. Trading was quieter than usual.

Follow DBVT's trial news. Pro members can get an alert when DBV Technologies files news, and see its trials, share raises, and its CEO's filings.

Get an alert when DBVT files news on its trialsSee it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Cash$166M, about 3 quarters at the last year's spendingOn Sep 30 · the company says “into the third quarter of 2027”

Why does DBVT lag the market?

Up 6% over three years while the S&P 500 rose 58%.

  • It filed a prospectus for an at-the-market program for new shares on Sep 5, 2025; free cash flow went from -$56.4M to -$121.7M.

Sources: Price history, Nov 20, 2026; Prospectus supplement, Sep 5, 2025; Annual reports, Dec 31, 2025

−2Long-term trend below a falling 200-day average, down over one year

1 more reason, free with an account →See every reason on DBVT →1 more reason why DBVT lags the market, from its filings, with the other side, the timeline, and its peers, for Pro members.

Key facts on DBVT

Key facts on DBVT
Since its 2022 highDown 71% a $97.8M loss → a $207.3M loss a year
Latest filing8-K, Oct 28 Reported its quarterly results

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Cash$166M, about 3 quarters at the last year's spendingOn Sep 30 · the company says “into the third quarter of 2027”

DBVT catalysts

Coming up

After its last 4 reports it closed -2.7% on average, higher 0 of 4 times.

What's next for DBVT, and how long its cash lasts

Its trials

A trial underway
Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)Phase 3 · Active · 480 people · main data estimated Nov 2026 · NCT07003919

2 more trials, 39 filings, for Pro members.

Cash runway Sep 30 balance sheet

About 3 quarters

$166M in cash and short-term investments, at its spending over the last year

What it means: how long the cash would last at the same pace, before any new money. The company's estimate is “into the third quarter of 2027” (8-K, Oct 28).

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

No shelf registration or at-the-market program on file in the last three years.

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

Chief Medical Officer Pharis Mohideen sold 464 shares on Jul 29. 1 more insider trade this year.

From Form 4: open-market buys and sales only.

For Pro members: every trade, and Daniel Tasse’s 2 filings and quotes.

Get an alert when DBVT files news on its trialsA free account. No card.Pro: $1 first month.Pro, 7 days free with a card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

12 more FDA dates and 98 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 144 dates, ranked →See all 144 dates, ranked →Start Pro

How DBVT ranks in Biotech

DBVT is #227 of 273 by Quality Score.

How DBVT ranks in Biotech
RankStockQuality Score
227DBV Technologies (DBVT) logoDBVTDBV-7

More in Biotech

When does DBVT report earnings, and what happens after?

Expected to report Thu Mar 25, after the close (in 124 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What DBVT reported on Oct 28, 2026

The quarter

The figures are not read from the release yet.

“Net cash used in operating & investing activities was $159.4 million for the nine months ended September 30, 2026, compared to $86.7 million for the nine months ended September 30, 2025, reflecting the continued advancement of these activities and the expansion of the Company's organization.”

The filing on EDGAR

Where the sales came from

DBVT's results filing gives no sales by line in a table we read. Its annual report gives the year's, in About.

The outlook

No outlook figures read from this release.

The numbers

Market value
$592M
today
Sales
$3.8M
down 31.6% on the year
Free cash flow
-$192M
last 12 months

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on DBVT: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

-5.4%-1.1%-3.4%
Apr 30Jul 16Oct 28
ReportedGapReaction5
days
Oct 28, 2026After close-12.2%-3.4%-6.7%
Jul 16, 2026After close+1.3%-1.1%-6.7%
Apr 30, 2026After close+0.9%-5.4%-4.8%

DBVT closed higher after 0 of its last 4 reports.

All 4 reports, and DBVT's Quality Score going into each

DBVT sales and profit by year

Sales and profit by year

Sales grew in two of the last six years, to $5.6M in 2025. It made a profit in two of the seven years.

DBVT has 1 of 14 chart checks firing

Volume1 of 3 shown
Tight range1 of 3 shown
Buying1 of 3 shown
The other 10 checks on DBVT, and all 14 on every stock.Get in free →See the top 3 →Start Pro

DBVT RSI on Nov 20: 37.7, below its 50-day and 200-day averages

Not scored

RSI 37.7, MACD below signal, below both averages. Not scored.

The deep dive on DBVT

6 more findings on DBVT, each with its source, for Pro members.

DBVT share count over time

3.3 times the count a year earlier.

Weighted shares, quarter to Sep 30, 2026, both from one filing

Shares of DBVT outstanding, as filed
Shares
outstanding
As
of
314.4MOct 26, 2026
296.1MJul 16, 2026
296MApr 30, 2026
296MApr 15, 2026
Offerings, shelves, and splits of DBVT, from its filings
From its
filings
Filed
Registered shares for a later sale (S-3ASR)Jul 27, 2026
Set up an at-the-market program for up to $150M of shares, about 25% of its market valueSep 5, 2025
Registered shares for a later sale (S-3)May 19, 2025

DBVT's officers and directors

Officers and directors with a Form 4 in the last 12 months.

See insider trades by person

About DBV Technologies

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

179 employeesChatillondbv-technologies.com

What DBV Technologies says it competes with

“The biotechnology and pharmaceutical industries are highly competitive and subject to significant and rapid change as researchers learn more about diseases and develop new technologies and treatments.”

From its annual report, SEC filing · Mar 26, 2026

Here is what Pro members see.

  • The same page for Pro members, on Microsoft

    Its Quality Score and rank, the line that drives it, and the live price.

  • The full chart

    A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.

  • Every line of the score

    Price action, the company, and signals, each with its points, on DBVT and every other stock.

  • FDA dates, counted down

    Each date in the company's words, its cash against the date, and an optional alert before it.

  • CEOs buying their own stock

    Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.

  • Congress trades

    A member's trades, newest first, each with its amount. Sort and filter the whole list.

  • 14 chart checks, read for you

    The ones firing on the stock, each in plain words, its rule a tap away.

  • Earnings, week by week

    Who reports each day, and how each stock took its last four reports.

  • The market map

    Every stock a box, colored by its Quality Score.

  • Themes, ranked live

    Each theme's stocks ranked by Quality Score, live. Here, AI chips.

  • The top 10, every day

    The ten highest Quality Scores at each close, kept day by day, week by week.

  • Optional alerts, your way

    Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.

  • Your watchlist, scored

    Your stocks by Quality Score, today's move, or name.

  • On your phone and your laptop

    The same account and watchlist on both, each laid out for its screen.

  • Prices refresh every 2.5 seconds during market hours.
  • Optional alerts by push, email, or the bell.
  • Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

  • What would turn DBVT's score around: 9 things
  • 5 more filings explained, a plain line each
  • 5 more things pulling DBVT's score down

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

Straight AnswersStraight Answers

As of Nov 21, 2026: DBVT's Quality Score is -7 (Poor), #227 of 273 in Biotech.

What does DBVT's Quality Score say?

DBVT scores -7 today, which Breakaway calls Poor. It is #227 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Up 6% over three years while the S&P 500 rose 58%. Cash lasts about 3 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is DBVT's Quality Score?

DBVT scores -7 today, which Breakaway calls Poor (below zero). That is #227 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind DBVT's -7.

When does DBVT report earnings?

Expected to report Thu Mar 25, after the close, a date Breakaway expects from the company's usual timing; the company has not confirmed it. DBVT closed higher after 0 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.

Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.

Every US stock, ranked live.

Insider and Congress trades, the chart, and the financials, in one score.

See all 3,170 stocks rankedSee all 3,170 stocks rankedStart Pro

See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.

What's next for DBV Technologies: from its SEC filings and ClinicalTrials.gov, the company's words, the registry's dates, and arithmetic, not a forecast. Companies often miss the dates they set.

The moves after past earnings reports are past behavior, not a forecast.

The price, the score, the chart checks and readings, and the industry rank on this page are delayed at least 15 minutes.

Our top-scored stocks' record: Oct 2021 to Sep 2026, before costs. Recorded live since Sep 9, 2026.

Breakaway publishes impersonal securities research and analytical tools: one formula, the same score for everyone. It is not personalized investment advice, and nothing here is a recommendation to buy or sell any security.

Market data from a licensed vendor. The age of every quote is shown on the page.

This browser is too old to show this page right. Update it, or open this page in Safari or Chrome.